


Welcome to Provider Office Hours

During the session, please use the Q&A panel to comment or ask a question:

Q&A Panel



- Open the **Q&A** panel
- Select Ask: **All Panelists**
- Enter Text, Click **Send**

Housekeeping

Reminder to Panelists:

Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Participants:

Please access today's slides and archived presentations at: <https://eziz.org/covid/>



Agenda

Special Guests

- Operational Update on COVID-19 Vaccination Network – Paul Markovich, President and CEO, Blue Shield of CA (TPA)

Q&A

Announcements

- TPA & My Turn Provider Resources – Leslie Amani

Vaccine Updates

- Allocations – Amy Pine
- Vaccine Eligibility – Louise McNitt, MD
- myCAvax – Claudia Aguiluz
- Clinical – Louise McNitt, MD
- Storage & Handling – Kate McHugh

Q&A




Operational Update on COVID-19 Vaccination Network

Paul Markovich, President and Chief Executive Officer, Blue Shield of California

Welcome to Provider Office Hours

During the session, please use the Q&A panel to comment or ask a question:

Q&A Panel



The screenshot shows a Cisco Webex interface with a Q&A panel open on the right. The panel is titled "Q&A" and shows "All (0)". Below the panel, there is a dropdown menu for "Ask:" with "All Panelists" selected. A red arrow points to this dropdown. Below the dropdown is a text input field with the placeholder text "Select a panelist in the Ask menu first and then type your question." and a "Send" button. A red arrow points to the "Send" button. The main content area of the Webex window contains a list of instructions:

- Open the **Q&A** panel
- Select Ask: **All Panelists**
- Enter Text, Click **Send**

Announcements

FAQs: Providers want to know!

TPA

Q: Where can Providers direct their Third-Party Administrator related questions?

A: Providers can email general questions to TPA_Inquiry@blueshieldca.com, and questions specific to signing the TPA agreement to CovidVaccineNetwork@blueshieldca.com. *(Note: There is an underscore "_" between TPA and Inquiry in above email address.)*

My Turn

Q: How do electronic health/medical records (EHR/EMRs) interface with My Turn?

A: To learn about the way EHRs/EMRs interface with My Turn, Providers can sign-up for Introductory My Turn trainings offered MWF, 1:00PM-2:30PM, PST. Provider questions can be emailed to myturnonboarding@cdph.ca.gov.

Provider FAQs

★ Q: Can patients schedule a COVID-19 vaccine appointment for a second dose only in My Turn?

A: Yes, patients can schedule second-dose appointments in My Turn. Second dose walk-in appointments may be scheduled through My Turn's "Walk- in Appointment" functionality. When patients create the walk-in appointment in the system, they will be asked if they'd like to schedule a second dose appointment.



My Turn Office Hours

Three Sessions:

**Monday, March 15th, 22nd, & 29th
12:00PM-1:00PM**

[Click here to join](#)

Session Number: 145 995 8782

Password: Immunize2020!

Audio Connection: 415-655-0001

Access Code: 145 995 8782



Vaccine Updates


Allocations – Amy Pine

- **10,988,301** Administered Doses!!
- Vaccine equity measure enacted March 4
 - doubles allocation for disproportionately-impacted communities (allotting 40% of doses to them)
 - Ties Blueprint for Safer Economy opening activities to doses administered in hardest-hit communities

Vaccinations by doses administered

Number of vaccine doses given in California

■ % of total and number of doses administered



Updated March 11, 2021 with data from March 11, 2021. Excludes doses without an HPI score, including out-of-state residents or records with missing zip codes. Percentage for doses calculated as doses administered in a quartile divided by total doses administered statewide.

Allocations– Amy Pine

This week's allocations (03/10/2021)

	Doses	Boxes
Pfizer	515,970	441
Moderna	380,300	3,803
Total	896,270	4,244

**CA will not receive another Janssen allocation until March 23 (?)

- Supply remains limited for eligible population
- **Prioritize second doses** over immunizing additional patients with first doses

Posted on [Vaccinate all 58](#) website:

- Doses on-hand **by provider**
- Weekly allocations of vaccine by health jurisdiction and multi-county-entity (MCE)

Vaccine Eligibility – Louise McNitt, MD

Starting March 15, vaccine eligibility will expand to include:

- 16-64 y/o at the very highest risk for morbidity and mortality
- Individuals who reside or work in a high risk congregate residential setting
 - E.g., detention facility, homeless shelter, or behavioral health facility
 - Includes all people experiencing homelessness who may transition into congregate settings at short notice
- Public transit workers, including airport and commercial airline workers
- [Provider Bulletin \(ca.gov\)](#)
- [Fact Sheet \(ca.gov\)](#)


LHD Allocations in myCAvax

- All LHD allocations are now submitted in myCAvax
- Order Communications for providers:
 - Accidental deletion of orders
 - System generated emails-now working




v-safe Pregnancy Registry – Louise McNitt, MD

- One of several [pregnancy safety monitoring programs](#)
 - Other systems include VAERS, VSD, and a prospective CISA study
- CDC is inviting people who received [COVID-19 vaccination in the periconception period \(within 30 days before last menstrual period\) or during pregnancy](#) to participate in the **v-safe** [COVID-19 Vaccine Pregnancy Registry](#). If people enrolled in **v-safe** report that they were pregnant at the time of vaccination or after vaccination, the registry staff might contact them to learn more.
- CDC may also request permission to contact their healthcare providers.



Patient Counseling – Louise McNitt, MD

- Interim Clinical Considerations for Use of COVID-19 Vaccines
provides helpful patient counseling points for mRNA & Janssen vaccines
 - Efficacy
 - Local and systemic reactogenicity
 - Management of post-vaccination symptoms



Vaccine Efficacy Compared – COCA Webinar

Pfizer BioNTech COVID-19 vaccine: Phase III results

- **When:** Interim results: outcomes observed from September- November 2020
- **Who:** Persons aged ≥ 16 years
- **Where:** United States, Brazil, Argentina, South Africa, Turkey, Germany

Outcome	Events/Vaccine ^a (n/N)	Events/Placebo ^a (n/N)	Vaccine efficacy (95% CI)
Symptomatic Lab-confirmed ^{b,c}	8/17411	162/17511	95% (90, 98)
Hospitalization ^{b,c}	0/17399	5/17495	100% (-10, 100)
Death ^{b,c}	0/21621	0/21631	

^a18,198 and 18,325 persons were randomized to vaccine and placebo, respectively; 17,411 and 17,511 in each arm had no evidence of prior infection

^bCases diagnosed ≥ 7 days post dose 2 vaccination among persons without evidence of prior SARS-CoV-2 infection

^cCOVID-19 associated

Access archive here!

[What Every Clinician Should Know about COVID-19 Vaccine Safety & Effectiveness and How to Address Patient Questions & Concerns](#)

(from March 9, 2021, CDC)

Vaccine Efficacy Compared – COCA Webinar

Moderna COVID-19 vaccine: Phase III results

- **When:** Interim results: outcomes observed from September- November 2020
- **Who:** Persons aged ≥ 18 years
- **Where:** United States

Outcome	Events/Vaccine ^a (n/N)	Events/Placebo ^a (n/N)	Vaccine efficacy (95% CI)
Symptomatic Lab-confirmed ^{b,c}	11/14134	185/14073	94% (89, 97%)
Hospitalization ^{b,c}	1/14134	9/14073	89% (13, 99)
Death ^{b,c}	0/14134	1/14073	

^a18,198 and 18,325 persons were randomized to vaccine and placebo, respectively; 17,411 and 17,511 in each arm had no evidence of prior infection

^bCases diagnosed ≥ 14 days post dose 2 vaccination among persons without evidence of prior SARS-CoV-2 infection

^cCOVID-19 associated

Access archive here!

[What Every Clinician
Should Know about
COVID-19 Vaccine Safety
& Effectiveness and How
to Address Patient
Questions & Concerns](#)

(from March 9, 2021,
CDC)

Vaccine Efficacy Compared – COCA Webinar

Janssen COVID-19 vaccine: Phase III results

- **When:** Interim results: outcomes observed from November 2020-January 2021
- **Who:** Persons aged ≥ 18 years
- **Where:** United States, South Africa, Brazil, Chile, Colombia, Peru, and Argentina

Outcome	Events/Vaccine ^a (n/N)	Events/Placebo ^a (n/N)	Vaccine efficacy (95% CI)
Symptomatic Lab-confirmed ^{b,c,d}	173/19,514	509/19,544	66% (60, 72)
Hospitalization ^d	2/19,514	29/19,544	93% (71, 98)
Death ^d	0/21,895	7/21,888	

^a21,895 and 21,888 persons were randomized to vaccine and placebo

^bCases diagnosed ≥ 14 days post vaccination among persons without evidence of prior SARS-CoV-2 infection

^cPrimary efficacy population (per protocol); includes a total of 3113 person-years of observation in vaccine group and 3089 person-years in placebo group

^dCOVID-19 associated

Access archive here!

[What Every Clinician Should Know about COVID-19 Vaccine Safety & Effectiveness and How to Address Patient Questions & Concerns](#)

(from March 9, 2021, CDC)

Syringe Replacements – Kate McHugh

- Federal government shipped replacements (via McKesson) for Haiou safety syringes (lot 20IB0)
 - Sent to over 500 providers
 - Retroactive and some providers may not have received vaccine recently
- Done out of an abundance of caution after reports of the needle & hub separating from the syringe
- Use the replacements if you received them
- Continue to ensure needles are securely attached to the hubs prior to withdrawing vaccine

Janssen COVID-19 vaccine from Johnson & Johnson Overview – Kate McHugh

- 100 doses per minimum order, 50 doses per carton, 5 doses per vial
- Store between 2°C-8°C
- After puncture, use within 6 hours if punctured vial is placed into refrigeration (2°C-8°C), or within 2 hours if punctured vial is stored at room temperature
- Shipped by McKesson
- See EZIZ for job aids and product guides
 - [IMM-1355.pdf \(eziz.org\)](#) - Janssen product guide
 - [IMM-1323.pdf \(eziz.org\)](#) - COVID Vaccine Product Comparison Guide
 - [Janssen COVID-19 Vaccine: Transporting Vaccine \(cdc.gov\)](#) - Transport Guide
 - And many more!

Temperature Monitoring

– Kate McHugh

It is critical to use a digital data logger (DDL) at all times!

- Ensure it meets specifications outlined in the [CDC toolkit](#)
 - Must continuously record and monitor temperatures
- Record temperature min/max at the start & end of each workday
 - Keep this record attached to the storage unit
- Download data at least once per week to review trends
- DDL should be set to record temperatures at minimum every 30 minutes, ideally every 15 minutes



Temperature Excursions – Kate McHugh

Reporting Temperature Excursions job aid [IMM-1340](#) (EZIZ.org)


Reporting Temperature Excursion worksheet: [IMM-1337](#) (EZIZ.org)

- Janssen (Johnson & Johnson)
 - [Stability Information \(janssenmd.com\)](#) - Online Tool
- Moderna
 - [Temperature Excursion Tool | Moderna, Inc. \(modernamedinfo.com\)](#) - Online Tool
 - excursions@modernatx.com
- Pfizer
 - 1-800-438-1985

Provider Office Hours Q&A

Please use the Q&A panel to comment or ask a question:

Q&A Panel



The screenshot shows a Cisco Webex interface with a Q&A panel open on the right. The panel has a title bar that says "Q&A" and "All (0)". Below the title bar is a text input field with a placeholder that says "Select a panelist in the Ask menu first and then type your question". To the right of the input field is a "Send" button. A red arrow points to the "Send" button. Another red arrow points to the "Ask" dropdown menu, which is currently set to "All Panelists".

- Open the **Q&A** panel
- Select Ask: **All Panelists**
- Enter Text, Click **Send**

Your Feedback is Important to Us

Poll:

How helpful was today's Provider Office Hours to your work?

- A. Very helpful
- B. Helpful
- C. Somewhat helpful
- D. Slightly helpful
- E. Not helpful at all



Thank you



for our next weekly
Provider Office Hours
Friday, March 19th
9:00 AM

OTHER IMPORTANT INFO
NOT COVERED IN
LIVE WEBINAR

Provider Resources

COVID-19 Provider Call Center – for questions related to the COVID-19 Vaccine Program

- Email: covidcallcenter@cdph.ca.gov
- Phone: (833) 502-1245
Monday – Friday from 8 AM–8 PM

myCAvax Technical Help – for technical questions

- Email: myCAvax.HD@accenture.com


My Turn – for questions regarding My Turn application

- Email about onboarding: myturnonboarding@cdph.ca.gov
- Email about general questions: myturninfo@cdph.ca.gov

Third-Party Administrator Blue Shield of California

- TPA_Inquiry@Blueshieldca.com
(Note: There is an underscore "_" between TPA and Inquiry.)


Provider FAQs



<https://eziz.org/assets/docs/COVID19/Vax58ProviderFAQs.pdf>

v-safe in Multiple Languages

- **v-safe is now available in English, Korean, Simplified Chinese, Spanish, Vietnamese**
- **v-safe** allows participants to:
 - receive text messages and web surveys with personalized health check-ins in the language chosen when they sign-up
 - report side effects after COVID-19 vaccination to CDC in almost real-time
 - receive a convenient reminder to get their second dose if they need one
 - access more information online in the above languages. To access these webpages, go to vsafe.cdc.gov. Then, scroll to the bottom of your screen and select your language of choice.



How to Promote v-safe

- Talk to community leaders, healthcare providers, and your other community partners about the availability of **v-safe** in five languages (English, Korean, Simplified Chinese, Spanish, Vietnamese) and encourage them to promote its use.
- Distribute the **v-safe** information sheet and other materials in needed languages to your partners.
- Share sample social media messages and the **v-safe** promotional video on your social media channels.
 - **v-safe** [website](#) in the above-mentioned languages
 - **v-safe** [information sheet](#) in the above-mentioned languages
 - **v-safe** [poster](#) in the above-mentioned languages

